Skip to content

Study on the Safety and Efficacy of Subclinical Dose Esketamine in TAVI Surgery

Study on the Safety and Efficacy of Subclinical Dose Esketamine in TAVI Surgery

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500110416
Enrollment
Unknown
Registered
2025-10-13
Start date
2025-10-15
Completion date
Unknown
Last updated
2025-10-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aortic valve disease

Interventions

Sponsors

The Second Hospital of Hebei Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
45 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1.Patients scheduled for elective transcatheter aortic valve implantation (TAVI); 2.American Society of Anesthesiologists (ASA) physical status classification II-IV; 3.Aged 45-90 years.

Exclusion criteria

Exclusion criteria: 1.Failure to obtain written informed consent from the patient; 2.Patients undergoing a second elective surgery during the same hospitalization period; 3.Myasthenia gravis or comorbid psychiatric disorders; 4.Severe hepatic and renal dysfunction, or a history of severe hypertension, diabetes mellitus, and coronary heart disease; 5.Alcoholism or substance abuse; 6.Patients with acute heart failure or acute myocardial infarction; 7.Patients or their family members requesting withdrawal from the study; 8.Anticipated difficult airway.

Design outcomes

Primary

MeasureTime frame
SBP;DBP;MAP;HR;

Secondary

MeasureTime frame
Dosage of Vasoactive Drugs;Recovery Indicators;

Countries

China

Contacts

Public ContactBo Lijun

The Second Hospital of Hebei Medical University

27901566@hebmu.edu.cn+86 186 3300 3022

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026